Review




Structured Review

Proteintech mmp2
Mmp2, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 537 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mmp2/MMP2+Antibody/10__3390_slash_biomedicines14102334-78-69-71
Average 96 stars, based on 537 article reviews
mmp2 - by Bioz Stars, 2026-11
96/100 stars

Images

Related Articles

other:

Article Title: Knockdown of CCT2 inhibits the malignant progression of hepatocellular carcinoma cells by impairing STAT3 activation
Article Snippet: Endogenous peroxidase activity quenching and non-specific antigen blocking were performed using IHC Detect kit for Rabbit/Mouse Primary Antibody (cat. no. PK10006; Proteintech Group, Inc.).

Western Blot:

Article Title: Cancer-associated fibroblasts drive immune resistance in MSS colorectal cancer via the FAIM2-CES1-ER stress pathway
Article Snippet: MMP9 , proteintech , 10375-2-Ap , 1:1000 , WB. .. MMP2 , proteintech , 10373-2-AP , 1:1000 , WB. .. PERK , proteintech , 24390-1-AP , 1:1000 , WB.

Sequencing:

Article Title: Knockdown of CCT2 inhibits the malignant progression of hepatocellular carcinoma cells by impairing STAT3 activation
Article Snippet: .. The primary antibodies were as follows: CCT2 (cat. no. 24896-1-AP), β-actin (cat. no. 66009-1-Ig), MMP2 (cat. no. 10373-2-AP), myeloid cell leukemia sequence 1 (MCL1; cat. no. 16225-1-AP) and SRY-box transcription factor 2 (SOX2; cat. no. 11064-1-AP; all Proteintech Group, Inc.) and STAT3 (cat. no. 4904) and phosphorylated (p-)STAT3 (Tyr705; cat. no. 4113; both Cell Signaling Technology, Inc.) The membranes were washed three times in TBST (0.1% Tween-20) for 5 min each at room temperature. ..

Cell-Signaling:

Article Title: Knockdown of CCT2 inhibits the malignant progression of hepatocellular carcinoma cells by impairing STAT3 activation
Article Snippet: .. The primary antibodies were as follows: CCT2 (cat. no. 24896-1-AP), β-actin (cat. no. 66009-1-Ig), MMP2 (cat. no. 10373-2-AP), myeloid cell leukemia sequence 1 (MCL1; cat. no. 16225-1-AP) and SRY-box transcription factor 2 (SOX2; cat. no. 11064-1-AP; all Proteintech Group, Inc.) and STAT3 (cat. no. 4904) and phosphorylated (p-)STAT3 (Tyr705; cat. no. 4113; both Cell Signaling Technology, Inc.) The membranes were washed three times in TBST (0.1% Tween-20) for 5 min each at room temperature. ..

Incubation:

Article Title: Discovery of the mechanism of Huangqi Guizhi Wuwu Decoction in the treatment of Diabetic Peripheral Neuropathy with Qi Deficiency and Blood Stasis based on the dynamic metabolic trajectory analysis.
Article Snippet: 17 Ethnopharmacological relevance: Huangqi Guizhi Wuwu Decoction (HGWD), a 18 classic Traditional Chinese Medicine formula, has shown clinical efficacy in the 19 treatment of diabetic peripheral neuropathy (DPN) with Qi deficiency and blood stasis 20 syndrome.. However, its pharmacodynamic material basis and underlying therapeutic 21 mechanisms remain unclear.. 22 Purpose: This study aimed to systematically elucidate the pharmacodynamic material 23 basis and therapeutic mechanisms of HGWD in the treatment of DPN using an 24 integrated Chinmedomics strategy.



Similar Products

93
Cusabio matrix metalloproteinase 2
Matrix Metalloproteinase 2, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mmp2/MMP2/pm42891895-65-4-17
Average 93 stars, based on 1 article reviews
matrix metalloproteinase 2 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

96
Santa Cruz Biotechnology mmp2
Mmp2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mmp2/MMP-2+Antibody/pm42886399-43-20-21
Average 96 stars, based on 1 article reviews
mmp2 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Proteintech mmp2
Mmp2, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mmp2/MMP2+Antibody/10__3390_slash_biomedicines14102334-78-69-71
Average 96 stars, based on 1 article reviews
mmp2 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

95
ABclonal Biotechnology mmp2
Mmp2, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mmp2/MMP2+Rabbit+pAb/pm42880136-55-32-34
Average 95 stars, based on 1 article reviews
mmp2 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

96
Proteintech matrix metalloprotease 2
Matrix Metalloprotease 2, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mmp2/MMP2+Polyclonal+antibody/pm42872763-59-81-87
Average 96 stars, based on 1 article reviews
matrix metalloprotease 2 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Proteintech mouse monoclonal anti mmp2 antibody
Mouse Monoclonal Anti Mmp2 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mmp2/MMP2+Antibody/pm42862722-715-166-170
Average 96 stars, based on 1 article reviews
mouse monoclonal anti mmp2 antibody - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

95
ABclonal Biotechnology mmp 2
In vivo evaluation of re-endothelialization and inhibition of intimal hyperplasia following stent implantation. (A–E) SEM images of the luminal surface treated with EV-loaded (A, B) or DPBS-loaded (D, E) nanofibrous membranes. The EV-treated group exhibited a continuous, smooth, and intact endothelial layer (A, B), whereas the DPBS group displayed incomplete coverage with substantial endothelial disruption (D, E). (C, F) H&E-stained cross-sections revealed the extent of neointimal formation above the stent struts (black arrows). The EV group (C) demonstrated significantly reduced intimal thickening compared with the pronounced hyperplasia observed in the DPBS group (F). (G–H) Statistical analysis confirmed that EV treatment significantly increased endothelial coverage (G) and suppressed intimal hyperplasia thickness (H). (I–K) EV treatment significantly upregulated the expression of the angiogenic factor VEGF (I), the endothelial marker CD31 (J), and the proliferation marker PCNA (K), confirming accelerated vascular repair. (L–N) EV treatment prevented phenotypic switching and matrix accumulation, as evidenced by reduced levels of the contractile/hyperplasia marker α-SMA (L). Furthermore, the EV group showed decreased expression of matrix <t>metalloproteinases</t> <t>MMP-2</t> and MMP-9 (M) and beneficial modulation of collagen composition, with increased Collagen I and the Collagen I/III ratio (N). (O–P) The EV group exhibited significantly downregulated levels of the profibrotic factor TGF-β1 (O) and the inflammatory cytokine IL-6 (P). N = 5 (G and H), and n = 3 (I-P). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.000.
Mmp 2, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mmp2/MMP2+Rabbit+pAb/pmc13544078-133-16-19
Average 95 stars, based on 1 article reviews
mmp 2 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

Image Search Results


In vivo evaluation of re-endothelialization and inhibition of intimal hyperplasia following stent implantation. (A–E) SEM images of the luminal surface treated with EV-loaded (A, B) or DPBS-loaded (D, E) nanofibrous membranes. The EV-treated group exhibited a continuous, smooth, and intact endothelial layer (A, B), whereas the DPBS group displayed incomplete coverage with substantial endothelial disruption (D, E). (C, F) H&E-stained cross-sections revealed the extent of neointimal formation above the stent struts (black arrows). The EV group (C) demonstrated significantly reduced intimal thickening compared with the pronounced hyperplasia observed in the DPBS group (F). (G–H) Statistical analysis confirmed that EV treatment significantly increased endothelial coverage (G) and suppressed intimal hyperplasia thickness (H). (I–K) EV treatment significantly upregulated the expression of the angiogenic factor VEGF (I), the endothelial marker CD31 (J), and the proliferation marker PCNA (K), confirming accelerated vascular repair. (L–N) EV treatment prevented phenotypic switching and matrix accumulation, as evidenced by reduced levels of the contractile/hyperplasia marker α-SMA (L). Furthermore, the EV group showed decreased expression of matrix metalloproteinases MMP-2 and MMP-9 (M) and beneficial modulation of collagen composition, with increased Collagen I and the Collagen I/III ratio (N). (O–P) The EV group exhibited significantly downregulated levels of the profibrotic factor TGF-β1 (O) and the inflammatory cytokine IL-6 (P). N = 5 (G and H), and n = 3 (I-P). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.000.

Journal: Materials Today Bio

Article Title: Human iPSC-EV-loaded nanofiber stent coatings accelerate vascular repair by enhancing EGFR/HIF-1α signaling and suppressing ROCK1-mediated remodeling

doi: 10.1016/j.mtbio.2026.103564

Figure Lengend Snippet: In vivo evaluation of re-endothelialization and inhibition of intimal hyperplasia following stent implantation. (A–E) SEM images of the luminal surface treated with EV-loaded (A, B) or DPBS-loaded (D, E) nanofibrous membranes. The EV-treated group exhibited a continuous, smooth, and intact endothelial layer (A, B), whereas the DPBS group displayed incomplete coverage with substantial endothelial disruption (D, E). (C, F) H&E-stained cross-sections revealed the extent of neointimal formation above the stent struts (black arrows). The EV group (C) demonstrated significantly reduced intimal thickening compared with the pronounced hyperplasia observed in the DPBS group (F). (G–H) Statistical analysis confirmed that EV treatment significantly increased endothelial coverage (G) and suppressed intimal hyperplasia thickness (H). (I–K) EV treatment significantly upregulated the expression of the angiogenic factor VEGF (I), the endothelial marker CD31 (J), and the proliferation marker PCNA (K), confirming accelerated vascular repair. (L–N) EV treatment prevented phenotypic switching and matrix accumulation, as evidenced by reduced levels of the contractile/hyperplasia marker α-SMA (L). Furthermore, the EV group showed decreased expression of matrix metalloproteinases MMP-2 and MMP-9 (M) and beneficial modulation of collagen composition, with increased Collagen I and the Collagen I/III ratio (N). (O–P) The EV group exhibited significantly downregulated levels of the profibrotic factor TGF-β1 (O) and the inflammatory cytokine IL-6 (P). N = 5 (G and H), and n = 3 (I-P). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.000.

Article Snippet: Proliferation and remodeling markers: PCNA (1:1000, ab29, Abcam), IL-6 (1:1000, A0286, ABclonal), TGF-β1 (1:1000, A2124, ABclonal), MMP-2 (1:1000, A6247, ABclonal), and MMP-9 (1:1000, A2095, ABclonal).

Techniques: In Vivo, Inhibition, Disruption, Staining, Expressing, Marker